Skip to main content
OpenTrials
Completed

NCT Number: NCT06192199

The Diagnostic Value of APTT/Fibrinogen Ratio in Pulmonary Embolism

From January 1, 2023 to December 30, 2023, patients who were suspected of pulmonary embolism and underwent CTPA examination at Nanyang Hospital of Southern Medical University were divided into pulmonary embolism group and non pulmonary embolism group. 1. Collect relevant data, including gender, age, primary disease, CTPA imaging and reports, BNP, troponin, electrocardiogram, cardiac ultrasound, PT, APTT, TT, fibrinogen, D-dimer, etc., and analyze demographic data, pulmonary embolism risk grading, APTT/fibrinogen ratio, and determine their cut-off values through statistical analysis of the two groups. 2. Follow up on the APTT/fibrinogen ratio after anticoagulation treatment and bleeding in the pulmonary embolism group.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Acute Pulmonary Embolism

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Nanfang hospital of Southern Medical University

Guangzhou, Guangdong, China

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Voluntary signing of informed consent form;
  • When signing the informed consent form, the age is equal to or greater than 18 years old, regardless of gender;
  • From January 1, 2023 to December 30, 2023, the patient was diagnosed with suspected pulmonary embolism at the Southern Hospital of Southern Medical University and underwent enhanced pulmonary artery scanning examination.

Exclusion criteria

  • Patients with gastrointestinal bleeding, severe trauma, acute coronary syndrome, severe liver disease (childC grade), and coagulation dysfunction;
  • Patients with pulmonary embolism diagnosed outside the hospital and regular anticoagulation;
  • Patients undergoing regular anticoagulant therapy such as atrial fibrillation and valve replacement;
  • Patients deemed unsuitable for participation in this study by the researchers.

Treatment and study plan

2018 edition of the Guidelines for Diagnosis

Diagnostic Test

According to the 2018 edition of the Guidelines for Diagnosis, Treatment and Prevention of Pulmonary Thromboembolism, and based on inclusion and exclusion criteria, enrolled patients were divided into a pulmonary embolism group and a non pulmonary embolism group

Primary outcomes

  1. Cutoff value of APTT/FIB between patients with and without acute pulmonary embolism

    Time frame: 2024.01-2026.12

Sponsors and collaborators

Lead sponsor

Nanfang Hospital, Southern Medical University

Other

Collaborators

  • Ganzhou City People's Hospital
  • Shenzhen Nanshan Hospital

Registry information

Important dates

Study start
2018
Primary completion
2025
Study completion
2025
First posted
Jan 5, 2024
Registry last updated
Jul 1, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.